Kiadis Pharma Obtains FDA Approval to Start a Phase III Clinical Trial for Reviroc(TM) in the United States
FDA Approves IND Application for Reviroc(TM)
AMSTERDAM, February 22 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma announced today that the US Food and Drug Administration (FDA) approved Kiadis Pharma's investigational new drug ("IND") application to allow the start of a clinical phase III study for its product Reviroc(TM) in the United States. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. This approval follows the successful End of Phase II meeting with the FDA for Reviroc(TM) and the subsequent submission of the IND package to the FDA. As part of the End of Phase II meeting the FDA offered its Special Protocol Assessment (SPA) for Reviroc(TM) for protocol design of a phase III clinical study. Kiadis Pharma will initiate the start of a phase III study upon completion of the SPA. The completed phase II study has shown an effective elimination of cancer cells from the patients autologous bone marrow graft prior to the transplantation and shows an encouraging overall survival after autologous bone marrow transplantations in Non-Hodgkin's lymphoma patients. "We are very pleased with this IND approval received from the FDA and look forward to completing the SPA as well to allow us to start enrolment of patients in the study," commented Manja Bouman, CEO of Kiadis Pharma. About Reviroc(TM) Reviroc(TM) is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc(TM) has been developed to remove tumor cells from the graft. About Kiadis Pharma Kiadis Pharma is a biopharmaceutical company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three blood cancer products in clinical development, offering novel treatment options for terminally ill cancer patients and address high-unmet medical needs. http://www.kiadis.com
SOURCE Kiadis Pharma
More by this Source
Kiadis Pharma Participates in Haploidentical Transplantation 2013 Forum
Dec 05, 2013, 02:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.